All In Biotech

Drug Trial Radar · NCT04019704

A Trial of AXS-05 in Patients With Major Depressive Disorder

AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Oct 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

327

Actual

Start

Jun 20, 2019

Primary completion

Nov 26, 2019

Study completion Dec 5, 2019

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).

Conditions

  • Depression
  • Major Depressive Disorder

Interventions

  • AXS-05Drug

    Oral AXS-05 tablets, taken daily for 6 weeks.

  • PlaceboDrug

    Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in MADRS Total Score From Baseline to Week 6Time frame: 6 weeks

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Phoenix, Arizona

  • Clinical Research Site

    Phoenix, Arizona

  • Clinical Research Site

    Little Rock, Arkansas

  • Clinical Research Site

    Bellflower, California

  • Clinical Research Site

    Beverly Hills, California

  • Clinical Research Site

    Garden Grove, California

  • Clinical Research Site

    Oakland, California

  • Clinical Research Site

    Oceanside, California

  • Clinical Research Site

    Panorama City, California

  • Clinical Research Site

    Redlands, California

  • Clinical Research Site

    Riverside, California

  • Clinical Research Site

    San Diego, California

  • Clinical Research Site

    Sherman Oaks, California

  • Clinical Research Site

    Upland, California

  • Clinical Research Site

    Coral Springs, Florida

  • Clinical Research Site

    Hollywood, Florida

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Lauderhill, Florida

  • Clinical Research Site

    North Miami, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Atlanta, Georgia

  • Clinical Research Site

    Boise, Idaho

  • Clinical Research Site

    Chicago, Illinois

  • Clinical Research Site

    Boston, Massachusetts

  • Clinical Research Site

    Las Vegas, Nevada

  • Clinical Research Site

    Berlin, New Jersey

  • Clinical Research Site

    Cherry Hill, New Jersey

  • Clinical Research Site

    Toms River, New Jersey

  • Clinical Research Site

    Jamaica, New York

  • Clinical Research Site

    Rochester, New York

  • Clinical Research Site

    Staten Island, New York

  • Clinical Research Site

    Hickory, North Carolina

  • Clinical Research Site

    Cincinnati, Ohio

  • Clinical Research Site

    Middleburg Heights, Ohio

  • Clinical Research Site

    Oklahoma City, Oklahoma

  • Clinical Research Site

    Media, Pennsylvania

  • Clinical Research Site

    Philadelphia, Pennsylvania

  • Clinical Research Site

    Memphis, Tennessee

  • Clinical Research Site

    Dallas, Texas

  • Clinical Research Site

    Fort Worth, Texas

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.